

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Robert H. Lustig

Serial No. : To Be Assigned

Cnfm. No. : To Be Assigned

Filed : Herewith

For : METHOD OF TREATING OBESITY IN
ADULT PATIENTS EXHIBITING PRIMARY
INSULIN HYPERSECRETION

Examiner:
To Be Assigned

Art Unit:
To Be Assigned



INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.97-1.98


Commissioner for Patents
Washington, D.C. 20231
Box: Patent Application

Dear Sir:

Pursuant to 37 CFR §§ 1.97-1.98, applicant hereby brings to the attention of the United States Patent and Trademark Office, the enclosed references listed on the attached PTO-1449 form.

Respectfully submitted,

Date: November 9, 2001


Edwin V. Merkel
Registration No. 40,087

NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603
Telephone: (716) 263-1128
Facsimile: (716) 263-1600

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO. 20609/191 (UTRC 00035)	SERIAL NO. To Be Assigned
	APPLICANT Robert H. Lustig	
	FILING DATE Herewith	GROUP ART UNIT To Be Assigned



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE
	1	4,853,371	08/01/89	Coy et al.			
	2	6,123,916	09/26/00	Krenning et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRAN- SLATION IF APPRO- PRIATE
	3	WO 98/51331	11/19/98	WIPO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

	4	Lotter et al., "Somatostatin Decreases Food Intake of Rats and Baboons," <u>Journal of Comparative and Physiological Psychology</u> 95:278-287 (1981)
	5	Levine et al., "Peripherally Administered Somatostatin Reduces Feeding by a Vagal Mediated Mechanism," <u>Pharmacology Biochemistry & Behavior</u> 16:897-902 (1982)
	6	"Correlations Between Autonomic Function, β -Cell Activity, Insulin Sensitivity, and Glucose Tolerance in Obese Subjects," The Endocrine Society's 82 nd Annual Meeting, Abstract, Document 1 (June 2000)
	7	Lustig et al., "Hypothalamic Obesity Caused by Cranial Insult in Children: Altered Glucose and Insulin Dynamics and Reversal by a Somatostatin Agonist," <u>The Journal of Pediatrics</u> 135:162-168 (August 1999)
	8	Lustig, "Childhood Obesity," Sero Symposia USA, Inc. and The Lawson Wilkins Pediatric Endocrine Society's Sero Symposia USA, San Francisco, CA. Pp. 133-139 (April 1999)
	9	Velasquez et al., "Monthly Injections of Long-Acting Octreotide Promote Insulin Suppression and Weight Loss in Adults with Severe Obesity," The Endocrine Society's Obesity II Poster Session, Abstract No. 2063, Board 498 (June 2000?)
	10	Sigal et al., "Acute Postchallenge Hyperinsulinemia Predicts Weight Gain: A Prospective Study," <u>Diabetes</u> 46:1025-1029 (1997)
	11	Le Stunff et al., "Early Changes in Postprandial Insulin Secretion, Not in Insulin Sensitivity, Characterize Juvenile Obesity," <u>Diabetes</u> 43:696-701 (1994)
	12	Campfield et al., "Insulin Normalization as an Approach to the Pharmacological Treatment of Obesity," <u>Obesity Research</u> 3(Supp. 4):591S-603S (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO. 20609/191 (UTRC 00035)	SERIAL NO. To Be Assigned
	APPLICANT Robert H. Lustig	
	FILING DATE Herewith	GROUP ART UNIT To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRAN- SLATION IF APPRO- PRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

		13	Lustig et al., "Hypothalamic Obesity is Due to Insulin Hypersecretion: Reversal With Octreotide," <u>Endocrinology/Diabetes</u> Pediatric Research Program Issue APS-SPR, New Orleans, LA, 43(4), Abstract No. 455 (April 1998)
		14	Lustig, "Treatment of Hypothalamic Obesity with Octreotide: Role of Insulin as Etiologic Agent," <u>Society for Neuroscience</u> 23 Society for Neuroscience Annual Meeting, New Orleans, LA, Abstract No. 102.34 (October 1997)
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			